Global Ivermectin Tablets Market Growth 2026-2032
Description
The global Ivermectin Tablets market size is predicted to grow from US$ 553 million in 2025 to US$ 701 million in 2032; it is expected to grow at a CAGR of 3.5% from 2026 to 2032.
Ivermectin is used to treat river blindness (onchocerciasis), intestinal infection from threadworms (strongyloidiasis), and other kinds of worm infections. Ivermectin is an anthelmintic. It works by interfering with the nerve and muscle functions of worms, by paralyzing and killing them.
Global ivermectin tablet production is projected to reach 1.13 billion tablets by 2025, with an average price of US$0.50 per tablet. Gross profit margins typically range from 25% to 40%.
The upstream of the ivermectin tablet industry chain mainly includes the fermentation and chemical synthesis of the active pharmaceutical ingredient (API) ivermectin, excipients, and pharmaceutical packaging materials. Among these, the cost and quality consistency of the API have the greatest impact on the price and compliance of the finished product. The downstream is the core of the demand side, with applications concentrated in the prevention and treatment of human parasitic diseases, including common parasitic diseases such as intestinal nematode infections, scabies, and head lice. The main usage scenarios are hospitals, primary healthcare institutions, pharmacies, and public health projects. In developing countries and tropical regions, this product is widely included in government or international organization-led disease control programs, characterized by large-scale centralized procurement and long-term stable usage. Downstream users are highly price-sensitive but have strict requirements for supply stability and quality standards. In some mature markets, ivermectin is more often used as a prescription drug or for specific indications, with relatively stable demand but limited growth.
The overall industry development trend is characterized by a differentiated demand structure. Public health and centralized procurement channels maintain large-volume, low-price supply, while retail and hospital sectors focus more on dosage accuracy and compliant labeling. Key driving factors include the long-term presence of parasitic diseases in some regions, the continued advancement of public health prevention and control projects, and improved accessibility of generic drugs. The main obstacles are: patents having expired long ago leading to severe homogenization; intense price competition; stricter regulations on ivermectin's indications in some markets; and public opinion and controversies surrounding its use outside of indications causing fluctuations in demand expectations.
LP Information, Inc. (LPI) ' newest research report, the “Ivermectin Tablets Industry Forecast” looks at past sales and reviews total world Ivermectin Tablets sales in 2025, providing a comprehensive analysis by region and market sector of projected Ivermectin Tablets sales for 2026 through 2032. With Ivermectin Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ivermectin Tablets industry.
This Insight Report provides a comprehensive analysis of the global Ivermectin Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ivermectin Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ivermectin Tablets market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ivermectin Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ivermectin Tablets.
This report presents a comprehensive overview, market shares, and growth opportunities of Ivermectin Tablets market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
0.2mg
0.5mg
1mg
2mg
3mg
6mg
12mg
Segmentation by Dosage Form:
Plain Tablets
Dispersible Tablets
Chewable Tablets
Enteric-Coated Tablets
Sustained-Release Tablets
Coated Tablets
Segmentation by Purity:
More than 99%
98%-99%
95%-98%
Segmentation by Application:
Livestock
Poultry
Pets
Wild Animals
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck (MSD)
Teva
Orion
Substipharm
Medical Valley Invest
Galenicum Derma
Centrafarm
Laboratorios Liconsa
Vygoris
Exeltis
Zydus UK
Dr. Reddy's Laboratories
Edenbridge Pharmaceuticals
Advagen Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Ivermectin Tablets market?
What factors are driving Ivermectin Tablets market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ivermectin Tablets market opportunities vary by end market size?
How does Ivermectin Tablets break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Ivermectin is used to treat river blindness (onchocerciasis), intestinal infection from threadworms (strongyloidiasis), and other kinds of worm infections. Ivermectin is an anthelmintic. It works by interfering with the nerve and muscle functions of worms, by paralyzing and killing them.
Global ivermectin tablet production is projected to reach 1.13 billion tablets by 2025, with an average price of US$0.50 per tablet. Gross profit margins typically range from 25% to 40%.
The upstream of the ivermectin tablet industry chain mainly includes the fermentation and chemical synthesis of the active pharmaceutical ingredient (API) ivermectin, excipients, and pharmaceutical packaging materials. Among these, the cost and quality consistency of the API have the greatest impact on the price and compliance of the finished product. The downstream is the core of the demand side, with applications concentrated in the prevention and treatment of human parasitic diseases, including common parasitic diseases such as intestinal nematode infections, scabies, and head lice. The main usage scenarios are hospitals, primary healthcare institutions, pharmacies, and public health projects. In developing countries and tropical regions, this product is widely included in government or international organization-led disease control programs, characterized by large-scale centralized procurement and long-term stable usage. Downstream users are highly price-sensitive but have strict requirements for supply stability and quality standards. In some mature markets, ivermectin is more often used as a prescription drug or for specific indications, with relatively stable demand but limited growth.
The overall industry development trend is characterized by a differentiated demand structure. Public health and centralized procurement channels maintain large-volume, low-price supply, while retail and hospital sectors focus more on dosage accuracy and compliant labeling. Key driving factors include the long-term presence of parasitic diseases in some regions, the continued advancement of public health prevention and control projects, and improved accessibility of generic drugs. The main obstacles are: patents having expired long ago leading to severe homogenization; intense price competition; stricter regulations on ivermectin's indications in some markets; and public opinion and controversies surrounding its use outside of indications causing fluctuations in demand expectations.
LP Information, Inc. (LPI) ' newest research report, the “Ivermectin Tablets Industry Forecast” looks at past sales and reviews total world Ivermectin Tablets sales in 2025, providing a comprehensive analysis by region and market sector of projected Ivermectin Tablets sales for 2026 through 2032. With Ivermectin Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ivermectin Tablets industry.
This Insight Report provides a comprehensive analysis of the global Ivermectin Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ivermectin Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ivermectin Tablets market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ivermectin Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ivermectin Tablets.
This report presents a comprehensive overview, market shares, and growth opportunities of Ivermectin Tablets market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
0.2mg
0.5mg
1mg
2mg
3mg
6mg
12mg
Segmentation by Dosage Form:
Plain Tablets
Dispersible Tablets
Chewable Tablets
Enteric-Coated Tablets
Sustained-Release Tablets
Coated Tablets
Segmentation by Purity:
More than 99%
98%-99%
95%-98%
Segmentation by Application:
Livestock
Poultry
Pets
Wild Animals
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck (MSD)
Teva
Orion
Substipharm
Medical Valley Invest
Galenicum Derma
Centrafarm
Laboratorios Liconsa
Vygoris
Exeltis
Zydus UK
Dr. Reddy's Laboratories
Edenbridge Pharmaceuticals
Advagen Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Ivermectin Tablets market?
What factors are driving Ivermectin Tablets market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ivermectin Tablets market opportunities vary by end market size?
How does Ivermectin Tablets break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
116 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Ivermectin Tablets by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Ivermectin Tablets by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
